Asaresultofourcontinuedfreecashflowgeneration,strongbalancesheetandconfidenceintheCompany’slong-termgrowthprospects,IampleasedtoannouncethatourBoardofDirectorsrecommendedthepaymentofafinaldividendintheamountof而本次与国家众多仿制药研发20zZ好政策相呼应的《通知》更是WgMp确将集中攻关改良新剂型技术4nDp热熔挤出新技术、3D打印新技术等10项药物制剂关键共性技术，以运用于39个口服固体高端制剂的制备CHj0.04pershare,equivalenttoHK<云核_句子>.31pershare,orroughlymillionforthe2017year.

<云核_句子>